Payment overview · 2025
General Payments
$577.77
30 reported records · 8 companies
Healthcare provider profile · identity verified
Joy Murphy, CFNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · COLUMBUS, MS · NPI 1508959040
Verified facts
What the public records show
CMS Open Payments records show Joy Murphy, CFNP received $577.77 in general payments during 2025 across 30 reported records.
Lilly USA, LLC accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $193.99 | 33.6% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.77 | 23.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.49 | 13.2% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $54.91 | 9.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.39 | 8.6% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $28.23 | 4.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.72 | 3.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.27 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $577.77 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $175.09 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $137.77 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $115.80 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $54.91 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.34 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.37 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $28.23 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.15 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 98 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 760 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 711 | 184 |
| Gabapentin | Gabapentin | 470 | 149 |
| Losartan Potassium | Losartan Potassium | 463 | 124 |
| Omeprazole | Omeprazole | 364 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 96 |
| Potassium Chloride | Potassium Chloride | 340 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 76 |
| Metformin Hcl | Metformin Hcl | 270 | 77 |
| Lisinopril | Lisinopril | 231 | 61 |
| Montelukast Sodium | Montelukast Sodium | 222 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 54 |
| Glipizide | Glipizide | 195 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 74 |
| Meloxicam | Meloxicam | 188 | 64 |
| Famotidine | Famotidine | 169 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 159 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 42 |
| Carvedilol | Carvedilol | 150 | 38 |
| Allopurinol | Allopurinol | 139 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 34 |
| Simvastatin | Simvastatin | 123 | 36 |
| Furosemide | Furosemide | 119 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 23 |
| Farxiga | Dapagliflozin Propanediol | 98 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 91 | 70 |
| Atenolol | Atenolol | 81 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 24 |
| Sertraline Hcl | Sertraline Hcl | 75 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 19 |
| Januvia | Sitagliptin Phosphate | 70 | 13 |
| Benazepril Hcl | Benazepril Hcl | 68 | 16 |
| Valsartan | Valsartan | 68 | 20 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 65 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | 13 |
| Clonidine Hcl | Clonidine Hcl | 63 | 16 |
| Trazodone Hcl | Trazodone Hcl | 62 | 21 |
| Alendronate Sodium | Alendronate Sodium | 61 | 18 |
| Spironolactone | Spironolactone | 60 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 15 |
| Ezetimibe | Ezetimibe | 54 | 17 |
| Glimepiride | Glimepiride | 54 | 16 |
| Jardiance | Empagliflozin | 54 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 51 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 25 |
| Ibuprofen | Ibuprofen | 49 | 20 |
| Pregabalin | Pregabalin | 49 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 22 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 12 |
| Donepezil Hcl | Donepezil Hcl | 41 | 12 |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Naproxen | Naproxen | 36 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 33 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 13 |
| Eliquis | Apixaban | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 29 |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 27 |
| Lactulose | Lactulose | 30 | suppressed |
| Nystatin | Nystatin | 30 | 16 |
| Meclizine Hcl | Meclizine Hcl | 29 | 12 |
| Alprazolam | Alprazolam | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 22 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Cefdinir | Cefdinir | 20 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 17 |
| Valacyclovir | Valacyclovir Hcl | 20 | 13 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 16 |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 17 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $577.77 · 30 records | Lilly USA, LLC | Dexcom G6 Transmitter, EVENITY, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, Tymlos, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error